Ara
Toplam kayıt 2, listelenen: 1-2
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
(Elsevier Inc., 2022)
Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib ...
Convalescent plasma therapy in patients with COVID-19 (Letter)
(Pergamon-Elsevier Science Ltd, 2021)
[No Abstract Available]